Om Gingercure ApS

 

Hej, jeg hedder Poul Baad Rasmussen, og jeg er indehaver af Gingercure ApS.

 

Jeg er uddannet Cand.scient. i molekylærbiologi, og jeg har arbejdet i mere end 30 år i medicinalindustrien indenfor forskning og udvikling.

 

Ved lidt af en tilfældighed fik jeg for nogle år siden øjnene op for ingefærs egenskaber som et potent smertelindrende og antiinflammatorisk middel, hvis ingefærs aktive substanser blev optaget over huden - lokalt hvor smerten var! Denne opdagelse lagde kimen til udviklingen af GingerCure.

 

GingerCure er en helt unik olieemulsion, der fremstilles ved en naturlig og skånsom proces, der sikrer, at ingefærs smertelindrende og antiinflammatoriske effekter bevares bedst muligt.



Mit CV:


November 2021 -

  • Manager, Gingercure ApS
  • Production and sale of product for pain relief

December 2018 - March 2020

  • Owner, Just-Ginger.com IVS; renamed to Zanozin IVS January 2020
  • Running website describing alternative method for treatment of overuse and acute injuries
  • Development of effective and safe product for pain relief

December 2011 - September 2018

  • Principal Scientist at AGC Biologics A/S

October 2010 - November 2011

  • Research Scientist at Lundbeck A/S

July 2008 - March 2010

  • Owner & Managing Director, Cell Line Solutions ApS
  • Consultancy on mammalian cell line/bioprocess development

August 1999 - June 2008

  • Research Scientist and, from July 2002, Principal Scientist at Maxygen ApS

July 1985 - August 1999

  • Research Scientist at Novo Nordisk A/S


Education:


September 2008 - June 2009

  • Module 1: Master of Professional Communication, Roskilde University, Denmark
  • Module2: Postponed due to sabbatical leave

September 1976 - January 1985

  • MSc; Microbiology/Molecular Biology, University of Southern Denmark


LIST OF PUBLICATIONS:

 

Patents/Patent applications

 

1.    Interferon beta variants and conjugates

Applicant: Maxygen Inc

Inventors: Pedersen A. H., Andersen K. V., Bornæs C., Rasmussen P. B.

US Patent 7,338,788; Patent issued March 4, 2008

2.    Interferon beta variants and conjugates

Applicant: Maxygen Inc

Inventors: Pedersen A. H., Andersen K. V., Bornæs C., Rasmussen P. B.

US Patent 7,238,344; Patent issued July 3, 2007

3.    Interferon beta variants and conjugates

Applicant: Maxygen Inc

Inventors: Rasmussen P. B., Rasmussen G., Andersen K. V., Bornæs C.

US Patent 7,144,574; Patent issued December 5, 2006

4.    Adiponectin fragments and conjugates

Applicants: Maxygen Aps/Maxygen Holdings

Inventors: Rasmussen P.B., Andersen K. V., Pedersen A. H., Schambye H. T., Halkier T., Bogsnes A.

International publication number: WO 03/055916

5.    New multimeric interferon beta-like molecules

Applicant: Maxygen Aps

Inventors: Bornæs C., Andersen K. V., Rasmussen P. B., Pedersen A. H.,

International publication number: WO 02/36628

6.    Expression of heparin-binding protein in recombinant mammalian cells

Applicant: Novo Nordisk A/S

Inventors: Flodgaard H. J., Rasmussen P. B., Bjørn S., Svendsen I.

International pubilcation number: WO 00/66627

7.    A cDNA and peptide with relation to cancer and weight loss.

Applicant: Novo Nordisk A/S

Inventors: Din N., Farrah T., Rasmussen P.B., Vissing H. & Clausen J.

International publication number: WO 98/11136

8.    A protein-lipid conjugate, consisting of heparin binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in treatment of conditions involving stress injury to cells.

Applicant: Novo Nordisk A/S

Inventors: Flodgaard H. & Rasmussen P.B.

International publication number: WO96/28544

9.    Heparin-Binding protein for the treatment of sepsis and processes for its preparation.

Applicant: Novo Nordisk A/S

Inventors: Flodgaard H. & Rasmussen P.B.

International publication number: WO95/28949

10.Method of producing proteins with FVIII activity and/or FVIII derivatives.

Applicant: Novo Nordisk A/S

Inventors: Rasmussen P.B. & Nordfang O.

Europe/Publication number: EP 0 480 923 B1

US/Attorney Docket No. 3316.024-US, Patent issued July 23, 1996

11.Stabilization of unstably inherited replicons

Applicant: Benzon Pharma A/S

Inventors: Molin S., Gerdes K.A., Rasmussen P.B. & Andersson P.K.

United States Patent 5,545,541, Patent issued August 13, 1996

 

 

 

Peer-reviewed articles

 

 

1.    Bouquin T., Rasmussen P.B., Bertilsson P.-A., Okkels J.S. (2006) A new method for the alternative tagging and targeting of recombinant proteins. Journal of Biotechnology 125(4), 516-28

2.    Kastrup J.S., Linde V., Pedersen A.K., Stoffer B., Iversen L.F., Larsen I.K., Rasmussen P.B., Flodgaard H.J. & Bjørn S.E. (2001) Two mutants of human heparin binding protein (CAP37): toward the understanding of the nature of lipid A/LPS and BPTI binding. Proteins 42, 442-51.

3.    Iversen L.F., Kastrup J.S., Bjørn S.E., Wiberg F.C., Larsen I.K., Flodgaard H.J. & Rasmussen P.B. (1999) Structure and function of N-linked glycosylation of HBP/CAP37/azurocidin: Crystal structure determination and biological characterization of nonglycosylated HBP. Protein Science 8, 2019-2026.

4.    West-Hansen S.E., Witt M.R., Dekermendjian K., Liljefors T., Rasmussen P.B. & Nielsen M. (1999) Arginine residue 120 of the human GABAA receptor a1 subunit is essential for GABA binding and chloride current gating. Neuroreport 10, 2417-2421.

5.    Lindmark A., Garwicz D., Rasmussen P.B., Flodgaard H. & Guldberg U. (1999) Characterization of the biosynthesis, processing, and sorting of human HBP/CAP37/azurocidin.  J. Leukoc. Biol. 66, 634-43.

6.    West-Hansen S.E., Rasmussen P.B., Hastrup S., Nabekura J., Noguchi K., Akaike N., Witt M.R. & Nielsen M. (1997) Decreased agonist sensitivity of human GABAA receptors by an amino acid variant, isoleucine to valine, in the a1 subunit. European J. of Pharmacology 329, 253-257.

7.    Iversen L.F., Brzozowski M., Hastrup S., Hubbard R., Kastrup J.S., Larsen I.K., Nærum L., Nørskov-Lauridsen L., Rasmussen P.B., Thim L., Wiberg F.C. & Lundgren K. (1997) Characterization of the allosteric binding pocket of human liver fructose-1,6-biphosphatase by protein crystallography and inhibitor activity studies. Protein Science 6, 971-982.

8.    Iversen L.F., Kastrup J.S., Bjørn S., Rasmussen P.B., Wiberg F.C., Flodgaard H.J. & Larsen I.K. (1997) The three-dimensional structure of HBP/CAP37/azurocidin, a multifunctional protein with a serine protease fold. Nature Structural Biology 4, 265-268.

9.    Hansen K., Kjalke M., Rasmussen P.B., Kongerslev L., & Ezban M. (1997) Proteolytic cleavage of recombinant two-chain factor VIII during fermentation is mediated by protease(s) from lysed cells. Cytotechnology 24, 227-234

10.Witt M.R., West-Hansen S.E., Rasmussen P.B., Hastrup S. & Nielsen M. (1996) Unsaturated free fatty acids increase benzodiazepine receptor agonist binding depending on the subunit composition of the GABAA receptor complex. J. Neurochem. 67, 2141-2145.

11.Iversen L.F., Kastrup J.S., Larsen I.K., Bjørn S., Rasmussen P.B., Wiberg F.C. & Flodgaard H. (1996) Crystallisation and molecular replacement solution of human heparin binding protein. Acta. Cryst. D52, 1222-1223.

  1. Rasmussen P.B., Bjørn S., Hastrup S., Nielsen P.F., Norris K., Thim L., Wiberg F.C. & Flodgaard H. (1996) Characterization of recombinant human HBP/azurocidin, a pleiotropic mediator of inflammation enhancing LPS-induced cytokine release from monocytes. FEBS Letters 390, 109-112.

13.Thirstrup K., Carriére F., Hjort S., Rasmussen P.B., Nielsen P.F. Ladefoged C., Thim L & Boel E. (1995) Cloning and expression in insect cells of 2 pancreatic lipases and a procolipase from Myocastor Coypus. Eur. J. of Biochem. 227, 186-193.

14.Thirstrup K., Carriére F., Hjort S., Rasmussen P.B. Wöldike H., Nielsen P.F. & Thim L. (1993) One step purification and characterization of human pancreatic lipase expressed in insect cells. FEBS letters 327, 79-84.

15.Kaltoft K., Bisballe S., Dyrberg T., Boel E., Rasmussen P.B. & Thestrup-Pedersen K. (1992) Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In vitro Cell. Dev. Biol. 28A, 161-167.

16.Ahrens P., Kruse T.A., Schwartz M., Rasmussen P.B., & Din N. (1987) A new HindIII restriction fragment length polymorphism in the hemophilia A locus. Hum. Genet. 76, 127-128

17.Rasmussen P.B., Gerdes K. & Molin S. (1987) Genetic analysis of the parB+ locus of plasmid R1. Mol. Gen. Genet. 209, 122-128.

18.Gerdes K., Bech F.W., Jørgensen S.T., Løbner Olesen A., Rasmussen P.B., Atlung T., Boe L., Karlstrøm O., Molin S. & von Meyenburg K. (1986) Mechanism of post-segregational killing by the hok gene product of the parB system of plasmid R1 and its homology with relF gene product of the E. coli relB operon. EMBO J. 5, 2023-2029

19.Gerdes K., Rasmussen P.B. & Molin S. (1986) Unique type of plasmid maintenance function: Post-segregational killing of plasmid-free cells. Proc. Natl. Acad. Sci. USA 83, 3116-3120.